Significantly less ulcer bleeding was found in patients with chronic aspirin use who underwent eradication of Helicobacter pylori, according to HEAT trial results.
Up to 80.6% of Phase 3 ADvocate trial responders, based on dosing interval, stayed clear or almost clear of lesions from weeks 16 to 52, according to the IGA scale.
In the phase 3 EoE KIDS trial, dupilumab showed remarkable efficacy in paediatric patients with eosinophilic oesophagitis.
A second phase 2 trial showed prurigo nodularis patients treated with dupilumab had a remarkable itch improvement from baseline to week 24.
For the first time, a study assessed longitudinal changes in microbiota during therapy with immune checkpoint inhibitors (ICIs).
Follow-up >6 months for necrotising pancreatitis infections with immediate or delayed drainage showed no influence on mortality or major complications.
Drugs for mental health? That may still seem strange to some. We explain what physicians need to know about novel forms of therapy with psychedelic substances.
Crohn's patients who responded only after a risankizumab second induction kept a CDAI clinical response in 75.8% on subcutaneous 360 mg at week 52.
Dr Adak Pirmorady-Sehouli talks in an interview about creative writing as a form of therapy in gynaecological oncology and how it can help in treatment.
Upadacitinib led to remission rates and endoscopic response in almost half of intensively pretreated patients with moderate-to-severe Crohn's at week 12.
Addition of enzalutamide to AAP does not improve overall survival of metastatic hormone-sensitive prostate cancer patients, STAMPEDE trial results show.
A study revealed that pancreatic cancer was initially missed in CT or MRI scans in 7.7% of the affected patients, reducing chances of curative surgery.
A new Europe-wide study highlights the worrying increase in the prevalence of various digestive diseases since 2000.
Maintenance therapy with an higher dose interval of adalimumab resulted in similar persistent flare rares in Crohn's Disease patients in stable remission.
Addition of maintenance olaparib to bevacizumab provides clinically meaningful overall survival benefit in patients who are HRD-positive.
Though widely used in Japan, in Europe its application has been on the rise in recent years: How can colorectal ESD help in gastroenterology?
Etrasimod leads to significant reductions in T and B cell subsets and paralleled reductions in absolute lymphocyte counts, showed the ELEAVATE trials.
H. pylori is considered the main cause of gastric cancer. If we eradicate it, other stomach-related diseases may become rarer. Are we close to achieving this?
Since vilobelimab displayed an acceptable safety profile in this population, the developers aim to discuss the results with the regulatory authorities.
Inhaled beta-1a did not meet primary endpoint in hospitalised COVID patients but may improve clinical outcomes more severe disease or risk factors cases.